Resonance Health Ltd (AU:RHT) has released an update.
Resonance Health Ltd has announced the opening of a new TrialsWest clinical trial site in Osborne Park, Western Australia, effectively doubling its capacity and market share in the global pharma clinical trials industry. The strategic location of the new site complements the existing site in Spearwood and aims to better serve Perth’s growing population. This expansion signifies the first phase of Resonance Health’s multi-year growth and acquisition strategy following the recent acquisition of TrialsWest.
For further insights into AU:RHT stock, check out TipRanks’ Stock Analysis page.